Evercore ISI Group maintains Medline at Outperform, raises price target to $44 from $38
Evercore ISI Group kept its Outperform rating on Medline and increased its price target to $44 from $38, suggesting a 9.0% upside from the Nov 4 close of $40.35. Recent analyst price targets for Medline range from $43 to $55.
How this was made

The 30-second read
Why it matters
The upgrade suggests modest upside potential but lacks concrete earnings data.
Market read
A modest analyst upgrade that may attract short‑term buying interest.
What to watch
No disclosed earnings or guidance; the upgrade is based on qualitative assessment.
Background
Evercore ISI upgraded Medline to Outperform and lifted the price target from $38 to $44.
Market effects
Analyst target raise may lift peer valuation in the medical supplies sector.
Limited to U.S. investors tracking Medline and related healthcare stocks.
Minimal global impact; primarily a U.S. equity micro‑cap note.
Counterpoint
The target raise could be premature if Medline's earnings miss expectations.
Key entities
- companyMedline
Medical supplies distributor, private (no US ticker).
- analystEvercore ISI Group
Equity research firm issuing the rating change.